Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

retlirafusp alfa (SHR-1701)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Dong-A, Jiangsu Hengrui Pharma

Drug class:

PD-L1 inhibitor, TGF-β R2 kinase inhibitor

Related drugs:

atezolizumab (236)

durvalumab (200)

benmelstobart (12)

sugemalimab (7)

envafolimab (6)

imsapepimut and etimupepimut, adjuvanted (4)

socazolimab (2)

atezolizumab and hyaluronidase-tqjs (1)

cosibelimab-ipdl (1)

adebrelimab (0)

CF33-hNIS-antiPDL1 (0)

PD-L1.t-haNK (0)

PF-07257876 (0)

Undisclosed anti-PD-L1 antibody (0)

›

EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	SHR-1701 Sensitive: C3 – Early Trials SHR-1701 Sensitive : C3	SHR-1701 Sensitive: C3 – Early Trials SHR-1701 Sensitive : C3
PD-L1 overexpression	Gastric Cancer	PD-L1 overexpression	Gastric Cancer	SHR-1701 Sensitive: C3 – Early Trials SHR-1701 Sensitive : C3	SHR-1701 Sensitive: C3 – Early Trials SHR-1701 Sensitive : C3
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	SHR-1701 Sensitive: C3 – Early Trials SHR-1701 Sensitive : C3	SHR-1701 Sensitive: C3 – Early Trials SHR-1701 Sensitive : C3
HER-2 negative + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	HER-2 negative + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	bevacizumab + SHR-1701 Sensitive: C3 – Early Trials bevacizumab + SHR-1701 Sensitive : C3	bevacizumab + SHR-1701 Sensitive: C3 – Early Trials bevacizumab + SHR-1701 Sensitive : C3
HER-2 negative + PD-L1 expression	Gastric Cancer	HER-2 negative + PD-L1 expression	Gastric Cancer	bevacizumab + SHR-1701 Sensitive: C3 – Early Trials bevacizumab + SHR-1701 Sensitive : C3	bevacizumab + SHR-1701 Sensitive: C3 – Early Trials bevacizumab + SHR-1701 Sensitive : C3
HER-2 negative + PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer	HER-2 negative + PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + SHR-1701 Sensitive: C3 – Early Trials bevacizumab + SHR-1701 Sensitive : C3	bevacizumab + SHR-1701 Sensitive: C3 – Early Trials bevacizumab + SHR-1701 Sensitive : C3